Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SHR-1139 injection in adults with ulcerative pyoderma gangrenosum
CTR20260697Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in pyoderma gangrenosum (PG), sponsored by Hengrui Therapeutics. Started Mar 2026; status: active.
02
Drugs
SHR-1139
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on CTR20260697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260697.